Meanwhile, IHC analysis of in vivo experiments again showed that CSGALNACT2 expression gradually decreased with the progression of ovarian cancer, with the lowest expression in advanced stages and metastases. The gene discussed is CSGALNACT2; the disease is ovarian carcinoma.